María Isabel González

ORCID: 0000-0003-1743-2005
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Alzheimer's disease research and treatments
  • Cholinesterase and Neurodegenerative Diseases
  • Pain Mechanisms and Treatments
  • Neuropeptides and Animal Physiology
  • Prion Diseases and Protein Misfolding
  • Computational Drug Discovery Methods
  • Anesthesia and Pain Management
  • Cutaneous lymphoproliferative disorders research
  • Neuroscience and Neural Engineering
  • CNS Lymphoma Diagnosis and Treatment
  • Ion channel regulation and function
  • Medicinal Plants and Neuroprotection
  • Lymphoma Diagnosis and Treatment
  • Soft tissue tumor case studies
  • Veterinary Pharmacology and Anesthesia
  • Adrenal Hormones and Disorders
  • Nonmelanoma Skin Cancer Studies
  • Cutaneous Melanoma Detection and Management
  • Neurological Disorders and Treatments
  • Nuclear Receptors and Signaling
  • CAR-T cell therapy research
  • Neuroscience and Neuropharmacology Research
  • 14-3-3 protein interactions
  • Cancer and Skin Lesions
  • Oral and Maxillofacial Pathology

Cambridge Consultants (United Kingdom)
2023-2024

Hospital Militar Central
2012-2019

Military University Nueva Granada
2019

GlaxoSmithKline (United Kingdom)
2004-2008

Discovery Centre
2006

University of Cambridge
1999-2000

Bridge University
2000

Generation and deposition of the amyloid beta (Abeta) peptide following proteolytic processing precursor protein (APP) by BACE-1 gamma-secretase is central to aetiology Alzheimer's disease. Consequently, inhibition BACE-1, a rate-limiting enzyme in production Abeta, an attractive therapeutic approach for treatment We have designed selective non-peptidic inhibitor, GSK188909, that potently inhibits beta-cleavage APP reduces levels secreted intracellular Abeta SHSY5Y cells expressing APP. In...

10.1111/j.1471-4159.2006.04260.x article EN Journal of Neurochemistry 2006-10-09

In the present study we tested effects of antihyperalgesic compound gabapentin on dorsal horn neurones in adult spinal cord. Slices were taken from control and hyperalgesic animals suffering streptozocin-induced diabetic neuropathy. At concentrations up to 100 microM, bath application failed affect resting membrane properties both groups animal. contrast, dramatically reduced magnitude excitatory postsynaptic current (EPSC) without altering EPSC animals. Using a paired pulse stimulation...

10.1038/sj.bjp.0703530 article EN British Journal of Pharmacology 2000-08-01

A transgenic mouse bearing mutant transgenes linked to familial forms of Alzheimer's disease (AD) for the amyloid precursor protein and presenilin-1 (TASTPM) showed Abeta plaque deposition age-related histological changes in associated brain pathology. The present was multiple forms, including species with a C-terminus at position 40 or 42, as well an N-terminus 1 truncated pyro-3-glutamate form. Endogenous rodent also deposits. Laser capture microdissection extracts that multimeric were...

10.14670/hh-23.67 article EN PubMed 2008-01-01

CI-1021 ([(2-benzofuran)-CH(2)OCO]-(R)-alpha-MeTrp-(S)-NHCH(CH (3))Ph) is a selective and competitive neurokinin-1 (NK(1)) receptor antagonist. This study examines its activity in animal models of inflammatory neuropathic pain. In mice, (1-30 mg/kg, s.c.) dose dependently blocked the development late phase formalin response with minimum effective (MED) 3 mg/kg. Two chemically unrelated NK(1) antagonists, CP-99,994 (3-30 mg/kg) SR 140333 (1-100 mg/kg), also phase, respective MEDs 10 PD...

10.1016/s0022-3565(24)39091-3 article EN Journal of Pharmacology and Experimental Therapeutics 2000-08-01

Ovariohysterectomy in the rat led to induction of abdominal postures and referred mechanical allodynia hind paws. The latter was differentiated into static dynamic subtypes. were present up 4–5 h, whilst two types lasted for at least 2 days. A single administration morphine 30 min before surgery dose-dependently (0.1–3 mg/kg, s.c.) blocked development allodynia. highest dose almost completely these responses. duration action 3 mg/kg short similar (1.5–2 h) when administered either or after...

10.1016/s0304-3959(00)00309-2 article EN Pain 2000-10-01

Enadoline is a highly selective and potent kappa-opioid receptor agonist. This report describes compares the activities of enadoline morphine in rat model postoperative pain. A 1 cm incision through muscle skin plantar surface right hind paw induced thermal hyperalgesia as well static dynamic allodynia lasting at least 2 days. Postoperative testing was carried out using test for hyperalgesia, von Frey hairs light stroking with cotton bud allodynia. single i.v. dose 15 min before surgery...

10.1016/s0304-3959(98)00237-1 article EN Pain 1999-03-01

We report the case of a 47-year-old male patient with S100 negative granular cell tumor oral cavity, focusing on dermoscopic features as well surgical approach, not previously reported in literature. The study contributes to literature dermoscopy and treatment for this provides practical approach differentiating non-neural tumors tumors.

10.1590/abd1806-4841.20197442 article EN cc-by Anais Brasileiros de Dermatologia 2019-02-01

Cleavage of the Amyloid Precursor Protein (APP) by β- and γ-secretase results in generation Aβ peptides that aggregate deposit as senile plaques brains Alzheimer's Disease (AD) patients. Consequently, is an attractive therapeutic target for treatment AD. Inhibitors lower levels plasma, CSF APP transgenic mice emerging clinical data shows inhibitors acutely reduce Aβ40 plasma. However, due to fundamental role plays intramembrane proteolysis a number other proteins, inhibitor approach can be...

10.1016/j.jalz.2008.05.1409 article EN Alzheimer s & Dementia 2008-07-01
Coming Soon ...